Most medical device professionals and companies are familiar with Premarket Approval (PMA) and 510(k) options. However, there are several other major regulatory pathways along with several sub-pathways (traditional, abbreviated, special, and safety and performance) that are available through the FDA.
Today’s guest is Mike Drues of Vascular Sciences. Together, he and Jon Speer introduce all of FDA’s regulatory pathways to bring a medical device to the U.S. market to help listeners decide which option is the best for them.
Pathways to Market: Why are they important? Without knowing all the options, it’s difficult to choose the best regulatory pathway for a medical device.
Which pathways are appropriate for a medical device? Depends on classification and risk, which are contingent on labeling, intended use, and technology.
Medical Device Pyramid: Which devices are regulated by FDA, and how are they classified? Class I, II, and III. Class 0 wellness devices are not FDA regulated.
De Novo: Alternative to 510(k) and appropriate for Class I/II Non-Exempt devices. However, De Novo is for new/novel devices without identified predicate.
Product Development Protocol (PDP): Uncommon pathway to market due to lack of guidance and regulation. Opportunity to not conform and forge your own way.
Humanitarian Device Exemption (HDE): PMA alternative and requirements include treating 8,000 or fewer patients per year. Most, not all, medical devices must be shown as safe and effective. HDE has no efficacy requirements.
Custom Device Exemption (CDE): Least common pathway with potential to be the most popular pathway to market due to personalized medicine (3-D printing).
Expanded Access Program (EAP) for Emergency/Compassionate Use: Ethical considerations because people are treated like guinea pigs, but an option to obtain early feasibility data and labeling.
“There are seven major pathways to bring a medical device onto the market here in the United States.” Mike Drues
“Unless somebody knows all of their options, and the advantages and disadvantages to each, then how can you possibly choose the best pathway?” Mike Drues
“You cannot separate the labeling and the technology. They go hand in hand when it comes to determining your classification and risk.” Mike Drues
“(PDP) is a very, very uncommon pathway to market, but I love to use the less common pathways to market, especially when there’s not a lot of guidance or regulation.” Mike Drues
ABOUT THE GLOBAL MEDICAL DEVICE PODCAST:
The Global Medical Device Podcast powered byGreenlight Guruis where today's brightest minds in the medical device industry go to get their most useful and actionable insider knowledge, direct from some of the world's leading medical device experts and companies.
Nick Tippmann is the Chief Marketing Officer for Greenlight Guru, a MedTech Lifecycle Excellence Platform (MLE) that provides an industry-specific solution to help medical technology innovators around the world use quality as an accelerator to move beyond baseline compliance and achieve True Quality. Tippmann is...